Wong Leung Hin Kelvin

• Responsible for variety of hematological drugs in HA and private sectors delivering outstanding performance throughout the year:

- Revlimid & Pomalyst, leveraged with the updates in funding enlistment which facilitated cases uptake resulting in over 150% YTD growth in both UCH & TKOH in 2023

- Spycel, with timely MI updates and clear selling message adjustment, successfully encouraged physicians to choose us over competitors and thus increase new cases uptake in my territories which eventually contributed to >50% of the team total

• Played instrumental role in winning new business through targeted prospecting and relationship building activities
• Balanced competing priorities while managing multiple accounts simultaneously, delivering consistently high-quality results
• Taken up new challenges and explore opportunities

• Responsible for promoting Benlysta, the SLE biologics which launched over 10 years, to Rheumatologists in both HA and private sectors
• Covered districts: Kowloon Central and West cluster; New Territories East cluster; Hong Kong Sanatorium Hospital; Union Hospital and all private specialists in Hong Kong Island
• Supported cross functional teams on HA drug formulary and Sam fund enlistment
• Liaised medical experts discussion actively in identifying suitable patient profiles for hospital internal guidelines
• Executed good key account management skills and manage to achieve doubt digit growth (96% in 2020 and 56% in 2021) by keeping good relationship with existing accounts and actively opening new accounts to drive new cases.

• Responsible for sales activities of allergy and rare disease portfolio to Otorhinolaryngologists, Respirologists, Pediatrics; Rheumatologists and Family Physicians in both HA and private sectors
• Covered districts: Kowloon Central and West Cluster; New Territories West Cluster and all private specialists in HK island
• Arranged marketing activities e.g Health talk, scientific meeting and speaker program
• Consistent performance with above target growth in responsible territories for consecutive years.

• Responsible for sales activities of allergy and rare disease portfolio to Otorhinolaryngologists, Respirologists, Pediatrics; Rheumatologists and Family Physicians in both HA and private sectors
• Covered districts: Kowloon Central and West Cluster; New Territories West Cluster and all private specialists in HK island
• Arranged marketing activities e.g
• Health talk, scientific meeting and speaker program
• Consistent performance with above target growth in responsible territories for the consecutive years.

• Responsible for sales activities of allergy portfolio to Pediatrics and Dermatologists in private sectors
• Responsible for promotion of newly launched men health drug to Urologists in private sectors
• Facilitate new launch of beta-blocker to cardiologists and family physicians
• Responsible for drug enlistment and sales activities of IBS drugs to Gastroenterologists in HA sectors
• Constantly achieved quarterly sales targets with growth and new accounts development
• Entitled quarterly sales award due to significant sales increment.